Eli Lilly Stock Could Rise 75%: New Analysis

A new analysis from Trefis suggests Eli Lilly (LLY) stock could have 75% upside from current levels, based on the strength of its diversified drug portfolio. Management argues that even without its metabolic business (diabetes and obesity drugs), Eli Lilly would still be one of the fastest-growing pharmaceutical companies in the industry.

Analyst's Rationale

The analysis highlights that Eli Lilly is not a single-product story. Its immunology, oncology, and neuroscience medicines collectively grew by 160%, demonstrating the depth of its R&D engine. This diversification reduces the risk of relying on one blockbuster drug.

Context

The analysis did not specify a price target but implied a 75% upside based on current valuation. This comes as Eli Lilly continues to expand its pipeline across multiple therapeutic areas.

What to Make of It

This analysis is an opinion from Trefis and not a buy or sell recommendation. Investors should consider regulatory and competitive risks, as well as the company's performance in upcoming quarters.